Buscar
Alkermes Plc
ALKSAñadir a la lista de seguimiento
48.990USD
-1.040-2.08%
Cierre 07-31 16:00（ET）Cotizaciones retrasadas 15 min
8.11BCap. mercado
52.69P/E TTM
Más Datos de Alkermes Plc Compañía
Alkermes plc is Ireland-based biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical candidates in development for neurological disorders. It focuses on commercial products, such as LYBALVI, ARISTADA/ARISTADA INITIO and VIVITROL, and advancing the development of pipeline programs focused on neurological disorders. LYBALVI is a once-daily, oral atypical antipsychotic drug for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia. It has a manufacturing facility in Wilmington, Ohio.
Información de Alkermes Plc
Símbolo de cotizaciónALKS
Nombre de la empresaAlkermes Plc
Fecha de salida a bolsaJul 16, 1991
Director ejecutivoPops (Richard F)
Número de empleados1800
Tipo de seguridadOrdinary Share
Fin del año fiscalJul 16
DirecciónConnaught House
CiudadDUBLIN
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísIreland
Código postalD04 C5Y6
Teléfono35317728000
Sitio Webhttps://www.alkermes.com/
Símbolo de cotizaciónALKS
Fecha de salida a bolsaJul 16, 1991
Director ejecutivoPops (Richard F)
Ejecutivos de Alkermes Plc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Richard F. Pops
Mr. Richard F. Pops
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
1.38M
--
Mr. David Joseph Gaffin
Mr. David Joseph Gaffin
Executive Vice President, Chief Compliance Officer, Chief Legal Officer, Secretary
Executive Vice President, Chief Compliance Officer, Chief Legal Officer, Secretary
227.49K
-0.89%
Mr. Shane M. Cooke
Mr. Shane M. Cooke
Independent Director
Independent Director
106.68K
+2.75%
Dr. Craig C. Hopkinson, M.D.
Dr. Craig C. Hopkinson, M.D.
Executive Vice President, Research and Development and Chief Medical Officer
Executive Vice President, Research and Development and Chief Medical Officer
73.39K
-5.45%
Mr. Frank Anders (Andy) Wilson, CPA
Mr. Frank Anders (Andy) Wilson, CPA
Lead Independent Director
Lead Independent Director
35.75K
+13.05%
Dr. Cato T. Laurencin, M.D., Ph.D.
Dr. Cato T. Laurencin, M.D., Ph.D.
Independent Director
Independent Director
33.77K
+13.82%
Dr. Christopher I. Wright, M.D., Ph.D.
Dr. Christopher I. Wright, M.D., Ph.D.
Independent Director
Independent Director
25.68K
-7.79%
Ms. Nancy S. Lurker
Ms. Nancy S. Lurker
Independent Director
Independent Director
18.22K
+25.61%
Dr. Nancy L. Snyderman, M.D.
Dr. Nancy L. Snyderman, M.D.
Independent Director
Independent Director
--
--
Mr. C. Todd Nichols
Mr. C. Todd Nichols
Senior Vice President, Chief Commercial Officer
Senior Vice President, Chief Commercial Officer
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Richard F. Pops
Mr. Richard F. Pops
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
1.38M
--
Mr. David Joseph Gaffin
Mr. David Joseph Gaffin
Executive Vice President, Chief Compliance Officer, Chief Legal Officer, Secretary
Executive Vice President, Chief Compliance Officer, Chief Legal Officer, Secretary
227.49K
-0.89%
Mr. Shane M. Cooke
Mr. Shane M. Cooke
Independent Director
Independent Director
106.68K
+2.75%
Dr. Craig C. Hopkinson, M.D.
Dr. Craig C. Hopkinson, M.D.
Executive Vice President, Research and Development and Chief Medical Officer
Executive Vice President, Research and Development and Chief Medical Officer
73.39K
-5.45%
Mr. Frank Anders (Andy) Wilson, CPA
Mr. Frank Anders (Andy) Wilson, CPA
Lead Independent Director
Lead Independent Director
35.75K
+13.05%
Dr. Cato T. Laurencin, M.D., Ph.D.
Dr. Cato T. Laurencin, M.D., Ph.D.
Independent Director
Independent Director
33.77K
+13.82%
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Alkermes Plc?
Los cinco principales accionistas de Alkermes Plc son: Mr. Richard F. Pops
¿Cuántas instituciones poseen acciones de Alkermes Plc (ALKS)?
A fecha de 2026Q1, 783 instituciones poseen acciones de Alkermes Plc, con un valor de mercado combinado de aproximadamente 182.39M, lo que representa el 109.43% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -11997400.00.
¿Cuál es la mayor fuente de ganancias de Alkermes Plc?
El 2026Q1, el segmento empresarial VIVITROL generó la ganancia más alta para Alkermes Plc, ascendiendo a 467.91M y representando el 31.70% de la ganancia total.